Turbine
Hungary
- Budapest
- 20/06/2023
- Series A
- $6,004,625
Turbine was founded for a simple reason; to understand complex cancers better than existing experimental tools in order to solve unmet oncology needs.
Through a multidisciplinary team that unites computer science and molecular biology, and the world's most intricate simulation of cell behavior, we identify treatment options for the 70% of cancers that are currently unexplored.
We use our platform, the Simulated Cell™, to uncover novel biological insights across both new and known targets. This allows us to provide a fresh biological context, define responsive patient populations, and design drug combination approaches that diminish resistance.
With a process proven by clinical stage predictions and a proprietary pipeline, we continue our mission of unlocking cancer complexity to deliver next-generation precision therapeutics.
- Industry Biotechnology Research
- Website https://turbine.ai/
- LinkedIn https://www.linkedin.com/company/turbine-inc/
Valinor | $13,000,000 | (Dec 12, 2025)
Keeper | $4,000,000 | (Dec 12, 2025)
Cyphlens | $3,800,000 | (Dec 12, 2025)
OnCorps AI | $55,000,000 | (Dec 12, 2025)
conveyd | $3,345,837 | (Dec 12, 2025)
Ritten | $35,000,000 | (Dec 12, 2025)
Safebooks AI | $15,000,000 | (Dec 12, 2025)
Double (1) | $6,500,000 | (Dec 12, 2025)
Yonda | $15,000,000 | (Dec 12, 2025)
Medra | $52,000,000 | (Dec 12, 2025)
Cynch AI | $9,000,000 | (Dec 12, 2025)
Empromptu.ai | $2,000,000 | (Dec 11, 2025)